Table 1.
Characteristics of studies included in the meta-analysis
| Study | Year | Country | Cancer type | Sample size | Cut off | Age | Follow-up month median (range) | Method | Treatment | NOS score | HR | HR method |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Greaves, Paul | 2013 | UK | HL | 113 | 125/HPF | NR | 16.5 (2–40) | Tissue microarrays | No | 8 | Estimated | OS |
| Kelley, T. W | 2007 | USA | HL | 98 | 25/HPF | 29 (4–84) | 103.2 (11–238.8) | Tissue microarrays | No | 6 | Estimated | OS, PFS |
| Chetaille, B | 2009 | France | HL | 132 | IHC score = 1 | NR | NR | Whole-tissue sections | No | 8 | Reported | OS, PFS |
| Muenst, S | 2009 | Switzerland | HL | 244 | 27 cell/mm2 | NR | NR | Whole-tissue sections | No | 6 | Reported | OS |
| Wang, Chaoyu | 2018 | China | HL | 95 | 25% | 31.5 (7–82) | NR | Whole-tissue sections | No | 5 | Reported | OS, PFS |
| Tzankov, A.1 | 2008 | Switzerland | HL | 280 | 27 cell/mm2 | 42 | 244 | Tissue microarrays | No | 8 | Estimated | OS |
| Nakayama, S | 2017 | Japan | DLBCL | 82 | 4000 cell/cm2 | 68.3 | NR | Whole-tissue sections | No | 6 | Reported | OS |
| Carreras, Joaquim | 2019 | Western | DLBCL | 106 | NR | 57 (26–88) | 97.56 (0.24–276.24) | Whole-tissue sections | No | 5 | Estimated | OS |
| El-Dien, Marwa M | 2017 | Egypt | DLBCL | 44 | NR | 54 (12–82) | 9.5 (1–105) | Whole-tissue sections | No | 6 | Estimated | OS |
| Nam, S. J | 2014 | Korea | DLBCL | 109 | NR | NR | 43 (16–178) | Whole-tissue sections | No | 6 | Estimated | OS, PFS |
| Chao, C | 2016 | USA | DLBCL | 80 | NR | NR | NR | Tissue microarrays | No | 7 | Estimated | OS |
| Gomez-Gelvez, J. C | 2016 | USA | DLBCL | 74 | 17% | 59.1 (20–91) | 49.2 (7.2–144) | Tissue microarrays | Yes | 6 | Reported | OS, PFS |
| Lee, Na-Ri | 2008 | Korea | DLBCL | 96 | 2.3% | 58 (20–83) | 16 (1–132) | Tissue microarrays | No | 6 | Reported | OS |
| Saifi, M | 2010 | France | FL | 100 | 86 cell/mm2 | 58 (48–69) | 24 (12–108) | Whole-tissue sections | No | 6 | Estimated | OS |
| Tzankov, A.2 | 2008 | Switzerland | FL | 86 | 4.5 cell/mm2 | 57 | 126 | Tissue microarrays | No | 8 | Estimated | OS |
| Carreras, J | 2019 | Spain | FL | 97 | 5% | 55 (26–93) | 5.6 (1.1–13.0) | Whole-tissue sections | No | 8 | Estimated | OS |
| Blaker, Y. N | 2016 | Norway | FL | 52 | Median | 54 (34–77) | 118 (68–300) | Tissue microarrays | Yes | 7 | Reported | OS, PFS |
| Richendollar, B. G | 2011 | USA | FL | 88 | 3% | 58 (24–89) | (6–19.7) | Tissue microarrays | No | 6 | Reported | OS |
| Kim, W. Y | 2009 | Korea | NKTCL | 64 | 50 cell/0.4mm2 | 50 (10–79) | NR | Whole-tissue sections | No | 8 | All | OS, PFS |
| Lam, Sio Teng | 2020 | China | NKTCL | 81 | 52.5/HPF | 45 (16–79) | 28.9 (1.127–11.493) | Whole-tissue sections | Yes | 6 | Reported | OS, PFS |
| Peng, R. J | 2011 | China | NKTCL | 27 | 22.89/HPF | 41 (13–68) | NR | Whole-tissue sections | No | 7 | Reported | OS, PFS |
| Lundberg, J | 2019 | Sweden | TCL | 35 | 200 cell/mm2 | 57 (18–73) | 141.6 (68.4—172.8) | Whole-tissue sections | No | 6 | Estimated | OS |
| Gjerdrum,L.M | 2007 | Denmark | TCL | 86 | Median | 66 (33–88) | 120 (2–360) | Whole-tissue sections | No | 8 | Reported | OS |
HL Hodgkin lymphoma, DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, NKTCL natural killer/T cell lymphoma, TCL T cell lymphoma